Human Reproduction, Vol. 17, No. 11, 2858-2864,
November 2002
© 2002 European Society of Human Reproduction and Embryology
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin
Cholesterol Center, Jewish Hospital, ABC Building, 3200 Burnet Avenue, Cincinnati, OH 45229, USA
BACKGROUND: We sought to determine whether metformin, which had facilitated conception in 72 oligoamenorrhoeic women with polycystic ovary syndrome (PCOS), would safely reduce the rate of first trimester spontaneous abortion (SAB) and increase the number of live births without teratogenicity. METHODS: Seventy-two oligoamenorrheic women with PCOS conceived on metformin (2.55 g/day). They were prospectively assessed in an outpatient clinical research centre. Outcome measures included number of first trimester SAB, live births, normal ongoing pregnancies 
13 weeks, gestational diabetes (GD), congenital defects (CD), birthweight and height, as well as weight, height, and motor and social development during the first 6 months of life. RESULTS: Of the 84 fetuses, to date there have been 63 normal live births without CD (75%), 14 first trimester SAB (17%), and seven ongoing pregnancies 13 weeks with normal sonograms without CD (8%). Previously, without metformin, 40 of the 72 women had 100 pregnancies (100 fetuses) with 34 (34%) live births and 62 (62%) first trimester SAB. In current pregnancies on metformin in these 40 women (46 pregnancies, 47 fetuses), there have been 33 live births (70%), two pregnancies ongoing 13 weeks (4%), and 12 SAB (26%) (P < 0.0001). There was no maternal lactic acidosis, and no maternal or neonatal hypoglycaemia. Fasting entry serum insulin was a significant explanatory variable for total (previous and current) first trimester SAB, odds ratio 1.32 (for each 5 µU/ml rise in insulin), 95% CI 1.09–1.60 (P = 0.005). On metformin, GD developed in 4% of pregnancies versus 26% of previous pregnancies without metformin, P = 0.025. There have been no major CD in the 63 live births or CD by sonography in the seven fetuses 
13 weeks. In the 63 live births, neither weight nor height differed from the normal neonatal population. At 6 month follow-up, height was greater (P = 0.008) and weight did not differ from the normal paediatric population; motor and social development were normal. CONCLUSIONS: Metformin therapy during pregnancy in women with PCOS was safely associated with reduction in SAB and in GD, was not teratogenic, and did not adversely affect birthweight or height, or height, weight, and motor and social development at 3 and 6 months of life.
Key words: gestational diabetes/metformin/polycystic ovarian syndrome/pregnancy/spontaneous abortion
1 To whom correspondence should be addressed. E-mail: glueckch{at}healthall.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L Hyer, J. Balani, A. Johnson, and H. Shehata Metformin treatment for gestational diabetes The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 220 - 225. [Abstract] [PDF]
|
|
|
|
 |
|
 V. A Sander, G. B Facorro, L. Piehl, E. Rubin de Celis, and A. B Motta Effect of DHEA and metformin on corpus luteum in mice Reproduction, September 1, 2009; 138(3): 571 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Koivunen, A. Pouta, S. Franks, H. Martikainen, U. Sovio, A-L. Hartikainen, M.I. McCarthy, A. Ruokonen, A. Bloigu, M-R. Jarvelin, et al. Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study Hum. Reprod., September 1, 2008; 23(9): 2134 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, and the MiG Trial Investigators Metformin versus Insulin for the Treatment of Gestational Diabetes N. Engl. J. Med., May 8, 2008; 358(19): 2003 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.A. Cocksedge, S.H. Saravelos, Q. Wang, E. Tuckerman, S.M. Laird, and T.C. Li Does free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage? Hum. Reprod., April 1, 2008; 23(4): 797 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Feig, G. G Briggs, and G. Koren Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? Ann. Pharmacother., July 1, 2007; 41(7): 1174 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Pedersen, S. Brar, P. Faris, and B. Corenblum Polycystic ovary syndrome: Validated questionnaire for use in diagnosis Can Fam Physician, June 1, 2007; 53(6): 1041 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Zisser Polycystic Ovary Syndrome and Pregnancy: Is Metformin the Magic Bullet? Diabetes Spectr, April 1, 2007; 20(2): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tian, H. Shen, Q. Lu, R. J. Norman, and J. Wang Insulin Resistance Increases the Risk of Spontaneous Abortion after Assisted Reproduction Technology Treatment J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1430 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Wood, D. A. Dumesic, D. H. Abbott, and J. F. Strauss III Molecular Abnormalities in Oocytes from Women with Polycystic Ovary Syndrome Revealed by Microarray Analysis J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Manno, F. Tomei, and E. Marchesan Polycystic ovary-related miscarriage: should metformin be proposed to such frustrated women? Hum. Reprod., February 1, 2007; 22(2): 623 - 623. [Full Text] [PDF]
|
|
|
|
|
|
E. Jauniaux, R. Farquharson, O. Christiansen, and N. Exalto Reply: Polycystic ovary-related miscarriage--should metformin be proposed to such frustrated women? Hum. Reprod., February 1, 2007; 22(2): 623 - 624. [Full Text] [PDF]
|
|
|
|
|
|
H. R Murphy, R. C Temple, and J. M Roland Improving outcomes of pregnancy for women with type 1 and type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2007; 7(1): 38 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Pasquali and A. Gambineri Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Daftary and H. S. Taylor Endocrine Regulation of HOX Genes Endocr. Rev., June 1, 2006; 27(4): 331 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Homburg Clomiphene citrate--end of an era? a mini-review Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy Diabetes Care, July 1, 2005; 28(7): 1821 - 1830. [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Ehrmann Polycystic Ovary Syndrome N. Engl. J. Med., March 24, 2005; 352(12): 1223 - 1236. [Full Text] [PDF]
|
|
|
|
|
|
C. Ortega-Gonzalez, S. Luna, L. Hernandez, G. Crespo, P. Aguayo, G. Arteaga-Troncoso, and A. Parra Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1360 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Setji, A. J. Brown, and M. N. Feinglos Gestational Diabetes Mellitus Clin. Diabetes, January 1, 2005; 23(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Glueck, P. Wang, N. Goldenberg, and L. Sieve Pregnancy Loss, Polycystic Ovary Syndrome, Thrombophilia, Hypofibrinolysis, Enoxaparin, Metformin Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 323 - 334. [Abstract] [PDF]
|
|
|
|
|
|
E. Vanky, K.A. Salvesen, R. Heimstad, K.J. Fougner, P. Romundstad, and S.M. Carlsen Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study Hum. Reprod., August 1, 2004; 19(8): 1734 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J. Glueck, N. Goldenberg, J. Pranikoff, M. Loftspring, L. Sieve, and P. Wang Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy Hum. Reprod., June 1, 2004; 19(6): 1323 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J. Glueck, N. Goldenberg, P. Wang, M. Loftspring, and A. Sherman Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy Hum. Reprod., March 1, 2004; 19(3): 510 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J.C. Eijkemans, B. Imani, A. G.M.G.J. Mulders, J.D. F. Habbema, and B. C.J.M. Fauser High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2) Hum. Reprod., November 1, 2003; 18(11): 2357 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Glueck, A. Moreira, N. Goldenberg, L. Sieve, and P. Wang Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin Hum. Reprod., August 1, 2003; 18(8): 1618 - 1625. [Abstract] [Full Text] [PDF]
|
|